ResMed Adopts New Operating Model To Accelerate Long-Term Growth; Rob Douglas, President And Chief Operating Officer, To Retire January 1, 2024.
Portfolio Pulse from Benzinga Newsdesk
ResMed (NYSE:RMD) has announced a new operating model to accelerate long-term growth, introducing dedicated leadership in Product, Revenue, and Marketing. Justin Leong, Katrin Pucknat, and Mike Fliss have been appointed as Chief Product Officer, Chief Marketing Officer, and Chief Revenue Officer, respectively. Rob Douglas, the current President and Chief Operating Officer, will retire on January 1, 2024, and will transition to a new role as special advisor to the CEO.
November 09, 2023 | 10:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ResMed's new operating model and leadership changes are aimed at accelerating long-term growth. The retirement of President and COO Rob Douglas may cause short-term uncertainty.
ResMed's new operating model and leadership changes are designed to accelerate growth, which could potentially boost the company's stock in the long term. However, the retirement of President and COO Rob Douglas could cause some short-term uncertainty among investors, potentially impacting the stock's performance.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100